Annual Meeting of the – DPhG Annual Meeting 2014 Annual Meeting of the German German Pharmaceutical Society – DPhG Pharmaceutical Society – DPhG Frankfurt/Main September 24 – 26, 2014 Trends and Perspectives in at Goethe University Pharmaceutical Sciences www.2014.dphg.de Conference Book Conference Book Conference Frankfurt/Main, September 24 – 26, 2014 at Goethe University ISBN 978-3-9816225-1-5 www.2014.dphg.de Annual Meeting of the German Pharmaceutical Society DPhG Trends and Perspectives in Pharmaceutical Sciences Conference Book Frankfurt/Main, September 24 26, 2014 at Goethe University www.2014.dphg.de Sponsors of the DPhG Annual Meeting 2014 MEDIEN FÜR DIE APOTHEKE Institutional Sponsors Förderer der DPhG-Jahrestagung 2014 CONFERENCE COMMITTEES Scientific Committee Prof. Dr. Thomas Efferth Prof. Dr. Christoph Friedrich Prof. Dr. Peter Gmeiner Prof. Dr. Ulrike Holzgrabe Prof. Dr. Ulrich Jaehde Prof. Dr. Jochen Klein Prof. Dr. Heyo Kroemer Prof. Dr. Peter Langguth Prof. Dr. Stefan Laufer Prof. Dr. Kristina Friedland Prof. Dr. Andreas Link Prof. Dr. Irmgard Merfort Prof. Dr. Klaus Mohr Dr. Olaf Queckenberg Prof. Dr. Peter Ruth Prof. Dr. Andrea Sinz Prof. Dr. Angelika Vollmar Prof. Dr. Hermann Wätzig Prof. Dr. Werner Weitschies Prof. Dr. Gerhard Winter Organisation Committee Seniorprof. Dr. Theodor Dingermann Prof. Dr. Jennifer Dressman PD. Dr. Gunter Eckert Prof. Dr. Robert Fürst Dr. Ann-Kathrin Häfner Dr. Bettina Hofmann Prof. Dr. Michael Karas PD. Dr. Thorsten Maier Prof. Dr. Rolf Marschalek Jun.-Prof. Dr. Eugen Proschak Dr. Bernd Sorg Dr. Michael Stein Dr. Mario Wurglics DPhG Annual Meeting 2014 3 ADDRESS OF WELCOME Dear colleagues, as President of the German Pharmaceutical Society (DPhG) and congress chair- man it is a pleasure for me to welcome you at Frankfurt to attend our Annual place for such a meeting which is part of the GU100 celebrations on the occa- sion of the 100th birthday of Goethe University. Furthermore, the meeting is cosponsored by one of our most important partners, the Pharmaceutical Society of Japan (PSJ). We can present you an interesting scientific programme which focuses on recent developments in all pharmaceutical disciplines. The meeting program covers topics such as antiinflammatory drugs, anticancer drugs and epigenetics, biotechnology, clinical pharmacy, drug design/medicinal chemistry/analytics, natural compounds, biopharmaceutics as well as many aspects of pharmaceuti- cal technology and drug delivery. I thank the scientific and the organisation committee as well as the chair Prof. Dr. Dieter Steinhilber persons of the sessions for creating an exciting programme. I would like to DPhG President thank all participants of the meeting for sharing their recent results and for their contributions. The abstract book provides you with an overview about the scientific posters and presentations and we hope, it will contribute to a success- ful meeting and to scientific exchange and discussions. 4 TABLE OF CONTENTS General Information ................................................................................................................................................................................. 6 Conference Program Overview ............................................................................................................................................................. 7 Plenary lectures ...................................................................................................................................................................................... 15 Scientific Sessions .................................................................................................................................................................................. 23 Antiinflammatory Drugs ................................................................................................................................................................................. 24 Neurodegeneration ........................................................................................................................................................................................... 29 Pharmaceutical Technology and Drug Delivery....................................................................................................................................... 33 Medicinal Chemistry (PSJ) .............................................................................................................................................................................. 38 Biomarker and Modeling ................................................................................................................................................................................ 42 Ligand Binding Assays ..................................................................................................................................................................................... 45 Computational Chemistry and Molecular Design ................................................................................................................................... 49 Natural Compounds ......................................................................................................................................................................................... 54 Analytics ............................................................................................................................................................................................................... 59 Case studies from Pharmaceutical Research and Development ........................................................................................................ 64 GPCR Medicinal Chemistry............................................................................................................................................................................. 69 Industrial Pharmacy ......................................................................................................................................................................................... 73 Biopharmaceutics and Pharmaceutical Technology .............................................................................................................................. 77 Anticancer and Epigenetic Drugs ................................................................................................................................................................. 82 Evidence-based Medication Management ................................................................................................................................................ 86 Optimizing Oral Drug Performance ............................................................................................................................................................. 90 Multitarget Drugs ............................................................................................................................................................................................. 94 Non-canonical GPCR-Signaling ................................................................................................................................................................... 99 Biopharmaceuticals/Biotechnology ........................................................................................................................................................... 103 Short lectures ........................................................................................................................................................................................ 108 Posters ..................................................................................................................................................................................................... 121 Antiinflammatory Drugs (AD01-AD19) .................................................................................................................................................... 122 Anticancer Drugs and Epigenetics (ACE01-ACE33) .............................................................................................................................. 128 Biotechnology (BT01-BT16) ......................................................................................................................................................................... 140 Clinical Pharmacy (CP01-CP15) .................................................................................................................................................................. 147 Drug Design/Medicinal Chemistry/Analytics (MC01-MC62) ............................................................................................................. 153 GPCR (G01-G14) .............................................................................................................................................................................................. 176 Natural Compounds (NC01-NC21) ............................................................................................................................................................ 182 Neuroactive Drugs (ND01-ND13) .............................................................................................................................................................. 189 Biopharmaceutics (BP01-BP09) .................................................................................................................................................................